Acasti Pharma Shares Outstanding 2014-2024 | GRCE

Acasti Pharma shares outstanding from 2014 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Acasti Pharma Annual Shares Outstanding
(Millions of Shares)
2024 10
2023 7
2022 6
2021 2
2020 2
2019 1
2018 0
2017 0
2016 0
2015 0
2015
2014 0
2014
2013 0
2013
Acasti Pharma Quarterly Shares Outstanding
(Millions of Shares)
2024-06-30 11
2024-03-31 10
2023-12-31 12
2023-09-30 8
2023-06-30 7
2023-03-31 7
2022-12-31 7
2022-09-30 7
2022-06-30 7
2022-03-31 6
2021-12-31 7
2021-09-30 5
2021-06-30 4
2021-03-31 2
2020-12-31 2
2020-09-30 2
2020-06-30 2
2020-03-31 2
2019-12-31 2
2019-09-30 2
2019-06-30 2
2019-03-31 1
2018-12-31 1
2018-09-30 1
2018-06-30 1
2018-03-31 0
2017-12-31 0
2017-09-30 0
2017-06-30 0
2017-02-28 0
2016-11-30 0
2016-08-31 0
2016-05-31 0
2016-03-31 0
2016-02-29
2015-12-31 0
2015-09-30 2
2015-06-30 0
2015-03-31 0
2014-12-31 0
2014-09-30 0
2014-06-30 0
2014-03-31 0
2014-02-28
2013-12-31 0
2013-09-30 0
2013-06-30 0
2013-03-31 0
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00